Enabling anticancer therapeutics by nanoparticle carriers: The delivery of paclitaxel

International Journal of Molecular Sciences

Volumn 12, Issue 7, 2011, Pages 4395-4413

  Liu, Yongjin ^a   Zhang, Bin ^a   Yan, Bing ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Anticancer drugs; Drug carrier; Drug delivery; Nanomaterials; Paclitaxel

Indexed keywords

CARBON NANOTUBE; CHITOSAN; CREMOPHOR; CURCUMIN; CYCLODEXTRIN; DIDODECYLDIMETHYLAMMONIUM BROMIDE; GOLD NANOPARTICLE; HOLLOW GOLD NANOSPHERE; MACROGOL; MAGNETIC NANOPARTICLE; NANOCARRIER; NANOSPHERE; PACLITAXEL; POLOXAMER; POLYGLACTIN; QUANTUM DOT; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; MAGNETITE NANOPARTICLE; METAL NANOPARTICLE; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CHEMICAL MODIFICATION; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; SOLID TUMOR; TUMOR XENOGRAFT; CHEMISTRY; NEOPLASMS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG CARRIERS; HUMANS; LACTIC ACID; MAGNETITE NANOPARTICLES; METAL NANOPARTICLES; NANOPARTICLES; NANOTUBES, CARBON; NEOPLASMS; PACLITAXEL; POLYGLYCOLIC ACID;

EID: 79960805268     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12074395     Document Type: Review

References (75)

1. Lopes, N.M.; Adams, E.G.; Pitts, T.W.; Bhuyan, B.K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 1993, 32, 235-242.
2. Rowinsky, E.K.; Cazenave, L.A.; Donehower, R.C. Taxol: A novel investigational antimicrotubule agent. J. Natl. Cancer 1990, 82, 1247-1259.
3. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4, 253-265.
4. Kingston, D.G.I. Tubulin-interactive natural products as anticancer agents (1). J. Nat. Prod. 2009, 72, 507-515.
5. Mugabe, C.; Hadaschik, B.A.; Kainthan, R.K.; Brooks, D.E.; So, A.I.; Gleave, M.E.; Burt, H.M. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int. 2009, 103, 978-986.
6. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37, 1590-1598.
7. Knemeyer, I.; Wientjes, M.G.; Au, J.L.S. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother. Pharmacol. 1999, 44, 241-248.
8. Singla, A.K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm. 2002, 235, 179-192.
9. Wong, J.; Brugger, A.; Khare, A.; Chaubal, M.; Papadopoulos, P.; Rabinow, B.; Kipp, J.; Ning, J. Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 2008, 60, 939-954.
10. Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: Toward smarter delivery of anticancer agents. J. Med. Chem. 2006, 49, 7253-7269.
11. Torchilin, V. Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 2007, 24, 1-16.
12. Tekade, R.K.; Kumar, P.V.; Jain, N.K. Dendrimers in oncology: An expanding horizon. Chem. Rev. 2008, 109, 49-87.
13. Musacchio, T.V.; Laquintana, A.; Latrofa, G.; Trapani, V.P. Torchilin, PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: Synergistic anticancer effect. Mol. Pharm. 2008, 6, 468-479.
14. Kedar, U.; Phutane, P.; Shidhaye, S.; Kadam, V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6, 714-729.
15. Hawkins, M.J.; Soon-Shiong, P.; Desai, N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 2008, 60, 876-885.
16. Jain, R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21, 2475-2490.
17. Acharya, S.; Sahoo, S.K. PLGA nanoparticles containing various anticancer agents and tumor delivery by EPR effect. Adv. Drug Deliv. Rev. 2011, 63, 170-183.
18. Yang, R.; Yang, S.G.; Shim, W.S.; Cui, F.; Cheng, G.; Kim, I.W.; Kim, D.D.; Chung, S.J.; Shim, C.K. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J. Pharm. Sci. 2009, 98, 970-984.
19. Danhier, F.; Lecouturier, N.; Vroman, B.; Jérome, C.; Marchand-Brynaert, J.; Feron, O.; Préat, V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J. Control. Release 2009, 133, 11-17.
20. Bhardwaj, V.; Ankola, D.D.; Gupta, S.C.; Schneider, M.; Lehr, C.M.; Kumar, M.N.V.R. PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm. Res. 2009, 26, 2495-2503.
21. Lee, E.; Lee, J.; Lee, I.H.; Yu, M.; Kim, H.; Chae, S.Y.; Jon, S. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem. 2008, 51, 6442-6449.
22. Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 2009, 136, 21-29.
23. Milane, L.J.; Duan, Z.; Amiji, M.M. Development of EGFR-targeted polymer blend nanocarriers for paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm. 2011, 8, 185-203.
24. Danhier, F.; Vroman, B.; Lecouturier, N.; Crokart, N.; Pourcelle, V.; Freichels, H.; Jérôme, C.; Marchand-Brynaert, J.; Feron, O.; Préat, V. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J. Control. Release 2009, 140, 166-173.
25. Zhang, Y.; Bai, Y.H.; Yan, B. Functionalized carbon nanotubes for potential medicinal applicatons. Drug Discov. Today 2010, 15, 428-435.
26. Wu, H.C.; Chang, X.; Liu, L.; Zhao, F.; Zhao, Y. Chemistry of carbon nanotubes in biomedical applications. J. Mater. Chem. 2010, 20, 1036-1052.
27. Zhou, H.Y.; Mu, Q.X.; Gao, N.N.; Liu, A.F.; Xing, Y.H.; Gao, S.L.; Zhang, Q.; Qu, G.B.; Chen, Y.Y.; Liu, G.; Zhang, B.; Yan, B. A nano-combinatorial library strategy for the discovery of nanotubes with reduced protein-binding, cytotoxicity, and immune response. Nano Lett. 2008, 8, 859-865.
28. Liu, Z.; Tabakman, S.; Welsher, K.; Dai, H. Carbon nanotubes in biology and medicine: In vitro and in vivo detection, imaging and drug delivery. Nano Res. 2009, 2, 85-120.
29. Partha, R.; Mitchell, L.R.; Lyon, J.L.; Joshi, P.P.; Conyers, J.L. Buckysomes: Fullerene-based nanocarriers for hydrophobic molecule delivery. ACS Nano 2008, 2, 1950-1958.
30. ®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006, 17, 1263-1268.
31. Liu, Z.; Chen, K.; Davis, C.; Sherlock, S.; Cao, Q.; Chen, X.; Dai, H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008, 68, 6652-6660.
32. Berlin, J.M.; Leonard, A.D.; Pham, T.T.; Sano, D.; Marcano, D.C.; Yan, S.; Fiorentino, S.; Milas, Z.L.; Kosynkin, D.V.; Price, B.K. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified paclitaxel. ACS Nano 2010, 4, 4621-4636.
33. Lay, C.L.; Liu, H.Q.; Tan, H.R.; Liu, Y. Delivery of paclitaxel by physically loading onto poly(ethylene glycol)(PEG)-graftcarbon nanotubes for potent cancer therapeutics. Nanotechnology 2010, 21, 065101.
34. Griset, A.P.; Walpole, J.; Liu, R.; Gaffey, A.; Colson, Y.L.; Grinstaff, M.W. Expansile nanoparticles: Synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J. Am. Chem. Soc. 2009, 131, 2469-2471.
35. Guo, Y.; Shi, D.; Cho, H.; Dong, Z.; Kulkarni, A.; Pauletti, G.M.; Wang, W.; Lian, J.; Liu, W.; Ren, L. In vivo imaging and drug storage by quantum-dot-conjugated carbon nanotubes. Adv. Funct. Mater. 2008, 18, 2489-2497.
36. Hilder, T.A.; Hill, J.M. Probability of encapsulation of paclitaxel and doxorubicin into carbon nanotubes. Micro Nano Lett. 2008, 3, 41-49.
37. Chen, J.; Wong, S.S.; Ojima, I. Carbon nanotube-based drug delivery systems and methods of making same. US Patent 20100021471, 2008.
38. Okon, E.; Pouliquen, D.; Okon, P.; Kovaleva, Z.V.; Stepanova, T.P.; Lavit, S.G.; Kudryavtsev, B.N.; Jallet, P. Biodegradation of magnetite dextran nanoparticles in the rat: A histologic and biophysical study. Lab. Invest. 1994, 71, 895-903.
39. Yin, H.; Yu, S.; Casey, P.S.; Chow, G.M. Synthesis and properties of poly(D,L-lactide) drug carrier with maghemite nanoparticles. Mater. Sci. Eng. C 2010, 30, 618-623.
40. Johannsen, M.; Gneveckow, U.; Eckelt, L.; Feussner, A.; Waldfner, N.; Scholz, R.; Deger, S.; Wust, P.; Loening, S.A.; Jordan, A. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int. J. Hyperth. 2005, 21, 637-647.
41. Alexiou, C.; Arnold, W.; Klein, R.J.; Parak, F.G.; Hulin, P.; Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lübbe, A.S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000, 60, 6641-6648.
42. Lübbe, A.S.; Bergemann, C.; Riess, H.; Schriever, F.; Reichardt, P.; Possinger, K.; Matthias, M.; Dörken, B.; Herrmann, F.; Gürtler, R. Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996, 56, 4686-4693.
43. Sonvico, F.; Mornet, S.; Vasseur, S.; Dubernet, C.; Jaillard, D.; Degrouard, J.; Hoebeke, J.; Duguet, E.; Colombo, P.; Couvreur, P. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chem. 2005, 16, 1181-1188.
44. Kohler, N.; Sun, C.; Wang, J.; Zhang, M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 2005, 21, 8858-8864.
45. Zhang, J.L.; Srivastava, R.S.; Misra, R.D.K. Core-shell magnetite nanoparticles surface encapsulated with smart stimuli-responsive polymer: Synthesis, characterization, and LCST of viable drug-targeting delivery system. Langmuir 2007, 23, 6342-6351.
46. Santra, S.; Kaittanis, C.; Grimm, J.; Perez, J.M. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small 2009, 5, 1862-1868.
47. Hua, M.Y.; Yang, H.W.; Chuang, C.K.; Tsai, R.Y.; Chen, W.J.; Chuang, K.L.; Chang, Y.H.; Chuang, H.C.; Pang, S.T. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 2010, 31, 7355-7363.
48. Chorny, M.; Fishbein, I.; Yellen, B.B.; Alferiev, I.S.; Bakay, M.; Ganta, S.; Adamo, R.; Amiji, M.; Friedman, G.; Levy, R.J. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc. Natl. Acad. Sci. 2010, 107, 8346-8351.
49. Hwu, J.R.; Lin, Y.S.; Josephrajan, T.; Hsu, M.H.; Cheng, F.Y.; Yeh, C.S.; Su, W.C.; Shieh, D.B. Targeted Paclitaxel by conjugation to iron oxide and gold nanoparticles. J. Am. Chem. Soc. 2008, 131, 66-68.
50. Tapan, K.J.; Marco, A.M.; Sanjeeb, K.S.; Diandra, L.L.P.; Vinod, L. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol. Pharm. 2005, 2, 194-205.
51. Jain, T.K.; Richey, J.; Strand, M.; Leslie-Pelecky, D.L.; Flask, C.A.; Labhasetwar, V. Magnetic nanoparticles with dual functional properties: Drug delivery and magnetic resonance imaging. Biomaterials 2008, 29, 4012-4021.
52. Cho, H.S.; Dong, Z.; Pauletti, G.M.; Zhang, J.; Xu, H.; Gu, H.; Wang, L.; Ewing, R.C.; Huth, C.; Wang, F.; Shi, D.L. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano 2010, 4, 5398-5404.
53. Johnson, B.; Toland, B.; Chokshi, R.; Mochalin, V.; Koutzaki, S.; Polyak, B. Magnetically responsive Paclitaxel-loaded biodegradable nanoparticles for treatment of vascular disease: Preparation, characterization and in vitro evaluation of anti-proliferative potential. Curr. Drug Deliv. 2010, 7, 263-273.
54. A. Radiolytic preparation of ultrafine colloidal gold particles in aqueous solution: Optical spectrum, controlled growth, and some chemical reactions. Langmuir 1999, 15, 6738-6744.
55. Oh, K.S.; Kim, R.S.; Lee, J.; Kim, D.; Cho, S.H.; Yuk, S.H. Gold/chitosan/pluronic composite nanoparticles for drug delivery. J. Appl. Polym. Sci. 2008, 108, 3239-3244.
56. Kuo, T.R.; Hovhannisyan, V.A.; Chao, Y.C.; Chao, S.L.; Chiang, S.J.; Lin, S.J.; Dong, C.Y.; Chen, C.C. Multiple release kinetics of targeted drug from gold nanorod embedded polyelectrolyte conjugates induced by near-infrared laser irradiation. J. Am. Chem. Soc. 2010, 132, 14163-14171.
57. You, J.; Shao, R.; Wei, X.; Gupta, S.; Li, C. Near-Infrared light triggers release of paclitaxel from biodegradable microspheres: Photothermal effect and enhanced antitumor activity. Small 2010, 6, 1022-1031.
58. Vivero-Escoto, J.L.; Slowing, I.I.; Wu, C.W.; Lin, V.S.Y. Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere. J. Am. Chem. Soc. 2009, 131, 3462-3463.
59. Yezhelyev, M.V.; Gao, X.; Xing, Y.; Al-Hajj, A.; Nie, S.; O'Regan, R.M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006, 7, 657-667.
60. Nyman, D.W.; Campbell, K.J.; Hersh, E.; Long, K.; Richardson, K.; Trieu, V.; Desai, N.; Hawkins, M.J.; Von Hoff, D.D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 2005, 23, 7785-7793.
61. Tekade, R.K.; Kumar, P.V.; Jain, N.K. Dendrimers in oncology: An expanding horizon. Chem. Rev. 2008, 109, 49-87.
62. Orringer, D.A.; Koo, Y.E.; Chen, T.; Kopelman, R.; Sagher, O.; Philbert, M.A. Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin. Pharmacol. Ther. 2009, 85, 531-534.
63. Dong, X.; Mattingly, C.A.; Tseng, M.T.; Cho, M.J.; Liu, Y.; Adams, V.R.; Mumper, R.J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009, 69, 3918-3926.
64. Luo, J.; Xiao, K.; Li, Y.; Lee, J.S.; Shi, L.; Tan, Y.H.; Xing, L.; Holland, C.R.; Liu, G.Y.; Lam, K.S. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjugate Chem. 2010, 21, 1216-1224.
65. Zhao, Z.; He, M.; Yin, L.; Bao, J.; Shi, L.; Wang, B.; Tang, C.; Yin, C. Biodegradable nanoparticles based on linoleic acid and poly(β-malic acid) double grafted chitosan derivatives as carriers of anticancer drugs. Biomacromolecules 2009, 10, 565-572.
66. Ganta, S.; Amiji, M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 2009, 6, 928-939.
67. Liu, Y.; Huang, L.; Liu, F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol. Pharm. 2010, 7, 863-869.
68. Reddy, L.H. Drug delivery to tumours: Recent strategies. J. Pharm. Pharmacol. 2005, 57, 1231-1242.
69. Cho, K.; Wang, X.; Nie, S.; Chen, Z.G.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14, 1310-1316.
70. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Xue, H.Y.; Babakhanian, K.; Wu, X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 2006, 317, 1372-1381.
71. Zhang, X.; Chen, J.; Zheng, Y.; Gao, X.; Kang, Y.; Liu, J.; Cheng, M.; Sun, H.; Xu, C. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res. 2009, 69, 6506-6514.
72. Bilensoy, E.; Gürkaynak, O.; Dogan, A.L.; Hincal, A.A. Safety and efficacy of amphiphilic-cyclodextrin nanoparticles for paclitaxel delivery. Int. J. Pharm. 2008, 347, 163-170.
73. Wang, Y.; Xin, D.; Liu, K.; Zhu, M.; Xiang, J. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjugate Chem. 2009, 20, 2214-2221.
74. Pathak, P.; Prasad, G.L.; Meziani, M.J.; Joudeh, A.A.; Sun, Y.P. Nanosized paclitaxel particles from supercritical carbon dioxide processing and their biological evaluation. Langmuir 2007, 23, 2674-2679.
75. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-760.